Arcutis Biotherapeutics Inc
ARQT23.780USD
+0.030+0.13%
Market hours （ET）Quotes delayed by 15 min
2.86BMarket Cap
LossP/E TTM
More Details of Arcutis Biotherapeutics Inc Company
Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high-unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment of plaque psoriasis, including psoriasis in the intertriginous areas, in individuals 12 years of age or older. ZORYVE cream is a once-daily topical formulation of roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor. The Company’s pipeline includes ARQ-255, ARQ-252, and ARQ-234. ARQ-255 is developed for alopecia areata. ARQ-252 is an alternative topical cream formulation of ivarmacitinib that the Company is developing for chronic hand eczema and vitiligo. ARQ-255 is developed for the treatment of alopecia areata.
Arcutis Biotherapeutics Inc Info
Ticker SymbolARQT
Company nameArcutis Biotherapeutics Inc
IPO dateJan 31, 2020
CEOMr. Todd Franklin Watanabe
Number of employees342
Security typeOrdinary Share
Fiscal year-endJan 31
Address3027 Townsgate Road
CityWESTLAKE VILLAGE
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code91361
Phone18054185006
Websitehttps://arcutis.com/
Ticker SymbolARQT
IPO dateJan 31, 2020
CEOMr. Todd Franklin Watanabe
Company Executives of Arcutis Biotherapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Bhaskar Chaudhuri, Ph.D.
Dr. Bhaskar Chaudhuri, Ph.D.
Independent Director
Independent Director
917.81K
+0.84%
Mr. Todd Franklin Watanabe
Mr. Todd Franklin Watanabe
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
603.10K
-1.88%
Dr. Howard G. Welgus, M.D.
Dr. Howard G. Welgus, M.D.
Independent Director
Independent Director
89.74K
-10.03%
Ms. Latha Vairavan
Ms. Latha Vairavan
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
64.93K
-0.14%
Mr. Patrick J. Heron
Mr. Patrick J. Heron
Independent Chairman of the Board
Independent Chairman of the Board
42.51K
+60.82%
Mr. Masaru (Mas) Matsuda, Esq., J.D.
Mr. Masaru (Mas) Matsuda, Esq., J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
28.59K
-20.14%
Ms. Sue-Jean Lin
Ms. Sue-Jean Lin
Independent Director
Independent Director
26.73K
+39.78%
Ms. Neha Krishnamohan
Ms. Neha Krishnamohan
Independent Director
Independent Director
23.36K
+48.32%
Ms. Terrie J. Curran
Ms. Terrie J. Curran
Independent Director
Independent Director
--
--
Ms. Halley E. Gilbert, J.D.
Ms. Halley E. Gilbert, J.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Bhaskar Chaudhuri, Ph.D.
Dr. Bhaskar Chaudhuri, Ph.D.
Independent Director
Independent Director
917.81K
+0.84%
Mr. Todd Franklin Watanabe
Mr. Todd Franklin Watanabe
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
603.10K
-1.88%
Dr. Howard G. Welgus, M.D.
Dr. Howard G. Welgus, M.D.
Independent Director
Independent Director
89.74K
-10.03%
Ms. Latha Vairavan
Ms. Latha Vairavan
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
64.93K
-0.14%
Mr. Patrick J. Heron
Mr. Patrick J. Heron
Independent Chairman of the Board
Independent Chairman of the Board
42.51K
+60.82%
Mr. Masaru (Mas) Matsuda, Esq., J.D.
Mr. Masaru (Mas) Matsuda, Esq., J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
28.59K
-20.14%
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Oct 11
Updated: Sat, Oct 11
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Jennison Associates LLC
10.00%
Suvretta Capital Management, LLC
9.42%
Rubric Capital Management LP
8.78%
Frazier Life Sciences Management, L.P.
8.06%
BlackRock Institutional Trust Company, N.A.
6.21%
Other
57.53%
Shareholders
Shareholders
Proportion
Jennison Associates LLC
10.00%
Suvretta Capital Management, LLC
9.42%
Rubric Capital Management LP
8.78%
Frazier Life Sciences Management, L.P.
8.06%
BlackRock Institutional Trust Company, N.A.
6.21%
Other
57.53%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
33.31%
Investment Advisor
30.23%
Hedge Fund
29.84%
Private Equity
8.06%
Research Firm
5.80%
Individual Investor
1.99%
Venture Capital
1.76%
Bank and Trust
0.40%
Pension Fund
0.28%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
476
134.55M
109.88%
-12.09M
2025Q2
481
131.17M
109.40%
-22.25M
2025Q1
487
132.87M
111.51%
-24.00M
2024Q4
453
136.04M
114.96%
-23.73M
2024Q3
433
136.12M
116.66%
-19.10M
2024Q2
416
134.94M
116.78%
-20.37M
2024Q1
392
131.83M
115.81%
+2.26M
2023Q4
366
104.30M
108.66%
+5.22M
2023Q3
364
79.57M
131.78%
-15.32M
2023Q2
359
84.02M
139.44%
-6.66M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Jennison Associates LLC
12.25M
10.22%
+1.14M
+10.30%
Sep 30, 2025
Suvretta Capital Management, LLC
11.54M
9.62%
+112.60K
+0.99%
Jun 30, 2025
Rubric Capital Management LP
10.75M
8.96%
-217.22K
-1.98%
Jun 30, 2025
Frazier Life Sciences Management, L.P.
9.87M
8.24%
+7.00
+0.00%
Aug 18, 2025
BlackRock Institutional Trust Company, N.A.
7.61M
6.35%
-296.14K
-3.75%
Jun 30, 2025
The Vanguard Group, Inc.
7.02M
5.86%
+231.02K
+3.40%
Jun 30, 2025
Polar Capital LLP
5.01M
4.18%
-1.70M
-25.35%
Jun 30, 2025
State Street Investment Management (US)
4.53M
3.78%
+52.73K
+1.18%
Jun 30, 2025
Gilder Gagnon Howe & Co. LLC
4.16M
3.47%
+59.71K
+1.46%
Jun 30, 2025
Morgan Stanley & Co. LLC
3.75M
3.13%
+672.66K
+21.86%
Jun 30, 2025
View more
Related ETFs
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
Simplify Health Care ETF
4.74%
Invesco Dorsey Wright Healthcare Momentum ETF
1.44%
Global X Guru Index ETF
1.37%
Virtus LifeSci Biotech Clinical Trials ETF
1.01%
SPDR S&P Biotech ETF
0.72%
First Trust Small Cap Growth AlphaDEX Fund
0.44%
Federated Hermes MDT Small Cap Core ETF
0.41%
Direxion Daily S&P Biotech Bull 3X Shares
0.38%
Inspire Small/Mid Cap ESG ETF
0.26%
ProShares Ultra Nasdaq Biotechnology
0.23%
View more
Simplify Health Care ETF
Proportion4.74%
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion1.44%
Global X Guru Index ETF
Proportion1.37%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion1.01%
SPDR S&P Biotech ETF
Proportion0.72%
First Trust Small Cap Growth AlphaDEX Fund
Proportion0.44%
Federated Hermes MDT Small Cap Core ETF
Proportion0.41%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.38%
Inspire Small/Mid Cap ESG ETF
Proportion0.26%
ProShares Ultra Nasdaq Biotechnology
Proportion0.23%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
